Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
about
Juvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantationA RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressorTargeted therapies in development for non-small cell lung cancerRAS diseases in childrenCotargeting MNK and MEK kinases induces the regression of NF1-mutant cancersOptimizing biologically targeted clinical trials for neurofibromatosis.PI3K p110δ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML.Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.NrasG12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis.NF1 regulation of RAS/ERK signaling is required for appropriate granule neuron progenitor expansion and migration in cerebellar development.Cells of origin in the embryonic nerve roots for NF1-associated plexiform neurofibromaTyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.Preclinical efficacy of MEK inhibition in Nras-mutant AML.Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia.Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers.Emerging EPO and EPO receptor regulators and signal transducers.Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1.The genomic landscape of juvenile myelomonocytic leukemia.Ginsenoside Rg1 improves bone marrow haematopoietic activity via extramedullary haematopoiesis of the spleen.MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.KRAS insertion mutations are oncogenic and exhibit distinct functional properties.An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemiaTargeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiencyRas-Mek-Erk signaling regulates Nf1 heterozygous neointima formation.Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.Abnormal Ras signaling in Costello syndrome (CS) negatively regulates enamel formation.Challenges in Drug Discovery for Neurofibromatosis Type 1-Associated Low-Grade GliomaThe role of nerve microenvironment for neurofibroma development.Neurofibromin-deficient myeloid cells are critical mediators of aneurysm formation in vivo.Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α.Translational hematology.Extramedullary hematopoiesis (EMH) in laboratory animals: offering an insight into stem cell research.Immunohistochemical Markers for Prospective Studies in Neurofibromatosis-1 Porcine Models.Turning the tide in myelodysplastic/myeloproliferative neoplasms.Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms.Modeling RASopathies with Genetically Modified Mouse Models.Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.
P2860
Q26851000-047EB8DB-47CB-4865-85B4-CBFC17522B37Q27003534-DB8F68C1-0E67-4780-ABED-2FB3BD3AC22CQ27022852-C90B1C66-CA11-43FD-8ACE-85F65BB1E334Q28252058-FA2CFCBF-01ED-4C8D-AEFD-B619610AC4A5Q28829666-7E51A37D-8E76-4771-8AD9-67FE1F2684E4Q30438898-875519FA-8D91-4EA2-AA7A-7DFEEC131C3BQ33556937-AA4156D8-8572-45A2-BF18-0222E79E1814Q33685977-6D445A38-26EE-4EE5-8CDF-9703E3C44205Q33917204-CB656723-FA81-4D9C-B542-682C87BFED35Q34430736-9DE43078-6900-4C9E-BE73-B7213BEAFF9BQ34625410-6212090F-36CF-4DF1-8D35-ACA1208D192DQ34662946-DDD3FD19-A010-427A-A7C2-F5D76B67CB32Q34737521-22921189-DCC1-48AC-890C-3580C03DC0E2Q34797988-51B42FDD-00EF-487E-8E16-DB52ACF3CA20Q35657827-466BDBE8-DD18-4606-9164-1C782EDD8A5AQ35692391-0673C3AD-B910-4FAE-88F1-E1EE4B678100Q35788976-C12DAC2C-93DF-4B43-BA97-3C23C842164FQ35987649-0A7634D6-7041-4D37-8CD2-C9FE5C0284D3Q36225715-5B6B3A2A-B827-482F-8725-87BEFD20A66DQ36232829-84FCCC7E-DBB6-4142-9E65-02E6A66BFB4EQ36497139-E234FAE4-4C8E-4E3D-A4BB-7FF4A3780345Q36564695-0994B78C-D092-4AC4-BC21-E5B63D6FCFCDQ36708989-003BDDBF-9041-4074-97D6-0582CE87BF03Q36928346-2478D12C-B5E6-49C2-A594-011365FA8C31Q36957609-6210DA5E-4ADF-4C25-9A45-7BB06334416DQ37304113-60E2F095-D22F-4345-9F7D-130855E5A97CQ37415475-81964DB8-6CA0-4E12-A642-E9E74E92043FQ37455251-1431752E-BBD1-4908-83F4-30586C2030ADQ37463973-4B833196-F86C-420C-8E93-B2F962900A6EQ37515982-582E8FAE-A25D-4B8A-97A2-C474E8521CA4Q37641630-EC6FE99A-6F25-4974-9B4B-4F1BFC9BAE74Q37649834-5B667431-46DC-4634-ACDB-A677142D1B2FQ37679937-AD3DB1B7-6E4E-4ED6-A864-2BEE794DB541Q38247744-4A5D045B-448D-4605-90FD-AB21072D6E8AQ38342415-AB265B40-5F6C-44AC-9A81-EEBFA579CAA2Q38636749-9D32342D-EB4D-4086-B91D-5DEA1F18ED8FQ38712988-8B1C6732-D2F7-498C-9534-D39BE5B7A322Q39030536-A1E78B82-15EC-4A41-B108-BC7220D84E49Q39031139-C48AF783-7B5A-463E-8271-0E7CD81B75EEQ39144248-3CC582AA-5AA6-40F0-8835-ECDA6B14DFFE
P2860
Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
@ast
Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
@en
type
label
Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
@ast
Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
@en
prefLabel
Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
@ast
Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
@en
P2093
P2860
P356
P1476
Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
@en
P2093
Benjamin S Braun
Emily Harding Theobald
Jennifer O Lauchle
Jon Akutagawa
Kevin Shannon
Kimberly Krisman
Scott Kogan
Tiffany Chang
P2860
P304
P356
10.1172/JCI63193
P407
P577
2012-12-10T00:00:00Z